PTC Therapeutics(PTCT) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

PTC Therapeutics Insiders Sold US$2.9m Of Shares Suggesting Hesitancy
Simply Wall StApr 18 06:59 ET
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $55
Moomoo NewsApr 18 02:41 ET · Ratings
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
PR NewswireApr 17 08:00 ET
Cautious Hold Rating for PTC Therapeutics Amidst FDA Reviews and Revenue Uncertainties
TipRanksApr 17 06:08 ET · Ratings
PTC Continues Onshape Momentum With Release of Onshape AI Advisor and Onshape Government
PR NewswireApr 15 08:30 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: PTC Therapeutics (PTCT) and Qiagen (QGEN)
TipRanksApr 7 06:50 ET · Ratings

Comments

Teddy123

Mar 20 20:26

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

$PTC Therapeutics (PTCT.US)$
Breakthrough PKU Treatment Enables 126% Higher Protein Intake in Clinical Trial

Teddy123

Feb 19 20:27

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

$PTC Therapeutics (PTCT.US)$
Could This Rare Disease Drug Be PTC's Next Breakthrough? FDA Priority Review Reveals Major Potential

Lnova

Dec 20, 2024 07:24

$PTC Therapeutics (PTCT.US)$
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...